logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Karina Romero

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 7.6

ph-index = 7

Forward Citations = 252(Granted Patents)


Location History:

  • Cambridge, MA (US) (2009 - 2016)
  • Arlington, MA (US) (2015 - 2016)
  • Burlington, MA (US) (2017)

Company Filing History:

goldMedal16 out of 1,976 
 
Amgen Inc.
 patents

Years Active: 2009-2017

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 9556135 - Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use (2017-01-31),
2. 9309263 - Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof (2016-04-12),
3. 9242961 - Aurora kinase modulators and method of use (2016-01-26),
4. 9212182 - Bicyclic sulfonamide compounds as sodium channel inhibitors (2015-12-15),
5. 9126935 - Aurora kinase modulators and methods of use (2015-09-08),
6. 9115127 - Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase (2015-08-25),
7. 9096615 - Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof (2015-08-04),
8. 8476434 - Protein kinase modulators and method of use (2013-07-02),
9. 8198448 - Fused heterocyclic derivatives and methods of use (2012-06-12),
10. 8022221 - Aurora kinase modulators and method of use (2011-09-20),
11. 7981891 - Aurora kinase modulators and method of use (2011-07-19),
12. 7880000 - Protein kinase modulators and method of use (2011-02-01),
13. 7868177 - Multi-cyclic compounds and method of use (2011-01-11),
14. 7776869 - Heteroaryl-substituted alkyne compounds and method of use (2010-08-17),
15. 7776857 - Aurora kinase modulators and method of use (2010-08-17),

Title: The Innovative Contributions of Karina Romero

Introduction

Karina Romero is a prominent inventor based in Cambridge, MA, known for her significant contributions to the field of pharmaceutical sciences. With a total of 16 patents to her name, she has made remarkable strides in developing compounds that target critical health issues, particularly those related to neurodegenerative diseases.

Latest Patents

Among her latest patents, Romero has developed amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists. These compounds are designed to modulate beta-secretase enzyme (BACE) activity, which is crucial in the formation of A-beta plaques associated with Alzheimer's Disease and other cognitive impairments. The invention includes pharmaceutical compositions that utilize these compounds for treating disorders linked to BACE activity, such as schizophrenia and various central nervous system conditions. Additionally, she has patented fused multi-cyclic sulfone compounds that serve as inhibitors of beta-secretase, further expanding her contributions to the treatment of BACE-mediated disorders.

Career Highlights

Karina Romero is currently employed at Amgen Inc., a leading biotechnology company. Her work focuses on innovative solutions for complex health challenges, particularly in the realm of neurodegenerative diseases. Her extensive research and development efforts have positioned her as a key figure in her field.

Collaborations

Throughout her career, Romero has collaborated with notable colleagues, including Hanh Nho Nguyen and Philip R Olivieri. These partnerships have enhanced her research capabilities and contributed to the successful development of her patented compounds.

Conclusion

Karina Romero's innovative work in developing beta-secretase antagonists and inhibitors has the potential to significantly impact the treatment of neurodegenerative diseases. Her contributions to the field exemplify the importance of research and innovation in addressing critical health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…